List of Excipients in Branded Drug OLMESARTAN MEDOXOMIL AND AMLODIPINE BESYLATE AND HYDROCHLOROTHIAZIDE

Generic Drugs Containing OLMESARTAN MEDOXOMIL AND AMLODIPINE BESYLATE AND HYDROCHLOROTHIAZIDE

Company	Ingredient	NDC	Excipient
Slate Run Pharmaceuticals LLC	olmesartan medoxomil and amlodipine besylate and hydrochlorothiazide	70436-014	CELLULOSE, MICROCRYSTALLINE
Slate Run Pharmaceuticals LLC	olmesartan medoxomil and amlodipine besylate and hydrochlorothiazide	70436-014	CROSCARMELLOSE SODIUM
Slate Run Pharmaceuticals LLC	olmesartan medoxomil and amlodipine besylate and hydrochlorothiazide	70436-014	FERRIC OXIDE RED
Slate Run Pharmaceuticals LLC	olmesartan medoxomil and amlodipine besylate and hydrochlorothiazide	70436-014	FERRIC OXIDE YELLOW

What are the Most Frequently-Used Excipients in OLMESARTAN MEDOXOMIL AND AMLODIPINE BESYLATE AND HYDROCHLOROTHIAZIDE?

# Of NDCs	Excipient
1	CELLULOSE, MICROCRYSTALLINE
1	CROSCARMELLOSE SODIUM
1	FERRIC OXIDE RED
1	FERRIC OXIDE YELLOW

Excipient Strategy and Commercial Opportunities for Olmesartan Medoxomil, Amlodipine Besylate, and Hydrochlorothiazide

Last updated: August 7, 2026

The fixed-dose combination of olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide is a mature antihypertensive product with established clinical demand and broad generic competition. Its commercial opportunity is primarily in cost-efficient generic manufacture, differentiated oral dosage forms, excipient substitution, supply-chain resilience, and improved adherence rather than new-chemical-entity exclusivity.

The product combines three antihypertensive mechanisms:

• Olmesartan medoxomil, an angiotensin II receptor blocker.
• Amlodipine besylate, a dihydropyridine calcium-channel blocker.
• Hydrochlorothiazide, a thiazide diuretic.

The branded product Tribenzor was developed by Daiichi Sankyo and approved by the U.S. Food and Drug Administration in 2010 for hypertension in patients requiring combination therapy.[1] The marketed strengths are 20/5/12.5 mg, 40/5/12.5 mg, 40/10/12.5 mg, and 40/10/25 mg.[1]

What is the commercial profile of the triple antihypertensive combination?

The product addresses patients whose blood pressure is inadequately controlled with two agents. Its value proposition is prescription simplification, improved adherence, and coordinated titration of an ARB, calcium-channel blocker, and diuretic.

Attribute	Product profile
Active ingredients	Olmesartan medoxomil, amlodipine besylate, hydrochlorothiazide
Therapeutic class	Fixed-dose antihypertensive combination
Original brand	Tribenzor
Original sponsor	Daiichi Sankyo
FDA approval	2010
Dosage form	Immediate-release film-coated tablet
U.S. strengths	20/5/12.5 mg; 40/5/12.5 mg; 40/10/12.5 mg; 40/10/25 mg
Main generic pathway	Abbreviated New Drug Application
Key commercial buyers	Generic manufacturers, pharmacy chains, wholesalers, hospitals, government purchasers
Main differentiation levers	Cost, supply reliability, bottle configuration, excipient profile, tablet size, packaging, and adherence-oriented dosage forms

The product is a mature small-molecule combination. Biosimilar risk is not relevant because all three active ingredients are chemically synthesized small molecules, not biologics. Competition is therefore driven by ANDA approvals, manufacturing economics, contract supply, and formulary access.

What excipients are used in the branded formulation?

The Tribenzor label identifies conventional tablet excipients, including lactose monohydrate, microcrystalline cellulose, low-substituted hydroxypropyl cellulose, hydroxypropyl cellulose, magnesium stearate, talc, titanium dioxide, and iron oxide colorants, with color composition varying by tablet strength.[1]

The formulation uses a conventional immediate-release platform:

Excipient function	Likely formulation role
Lactose monohydrate	Diluent and compressibility aid
Microcrystalline cellulose	Filler, dry binder, and disintegration support
Low-substituted hydroxypropyl cellulose	Disintegrant
Hydroxypropyl cellulose	Binder
Magnesium stearate	Lubricant
Talc	Anti-adherent and processing aid
Titanium dioxide	Opacifier and coating pigment
Iron oxides	Strength-specific tablet color coding

The inactive ingredients are not the primary source of product differentiation. Their commercial importance lies in controlling dissolution, blend uniformity, tablet robustness, coating appearance, and manufacturing yield.

Why does the formulation require careful excipient selection?

The three active ingredients create different formulation demands.

Olmesartan medoxomil is a prodrug with limited aqueous solubility. Its dissolution behavior can be affected by particle size, wetting, compression force, disintegrant performance, and the hydrophobicity of the lubricant system.

Amlodipine besylate is present at relatively low dose in the 5 mg and 10 mg strengths. Low-dose content uniformity is therefore a critical control point, particularly when the active is blended with higher-dose olmesartan and hydrochlorothiazide.

Hydrochlorothiazide is present at 12.5 mg or 25 mg. It contributes additional blend-uniformity and dissolution requirements but is generally compatible with standard immediate-release tablet manufacturing.

The formulation must maintain acceptable performance across four dose strengths without creating excessive tablet size. A manufacturer that changes excipient grade, lubricant concentration, granulation process, or coating system must evaluate the effect on dissolution, assay, content uniformity, hardness, friability, and stability.

What excipient strategies are available for generic manufacturers?

Generic manufacturers have several formulation options, but the strongest commercial strategy is usually a low-risk composition that closely reproduces the reference product's release profile.

Direct compression

Direct compression can reduce processing steps and manufacturing cost. It is attractive if the selected grades of microcrystalline cellulose, lactose, and disintegrant provide adequate flow and compressibility.

The principal risks are:

• Poor segregation control caused by differences in active and excipient particle size.
• Low-dose amlodipine content-uniformity failures.
• Variable tablet hardness.
• Slower dissolution caused by over-lubrication.
• Increased scale-up sensitivity.

Direct compression is most competitive when the manufacturer has strong powder-engineering capability and can secure consistent excipient grades.

Wet granulation

Wet granulation can improve flow, reduce segregation, and support content uniformity. It may be useful when the active pharmaceutical ingredients have poor flow or when the formulation contains a broad particle-size distribution.

The tradeoffs are higher capital and operating costs, longer processing time, and additional exposure to water and heat. Moisture control is important because process water, residual moisture, and drying conditions can influence stability and dissolution.

Dry granulation

Roller compaction can provide a middle path between direct compression and wet granulation. It avoids liquid exposure and may improve flow and uniformity. The main risks are over-compaction, slower disintegration, and changes in dissolution caused by granule density.

Co-processed excipients

Co-processed lactose-cellulose systems, silicified microcrystalline cellulose, and engineered disintegrants may improve flow and compression. Their use can support smaller tablets or higher throughput, but the sponsor must establish that the new excipient system does not alter product performance.

A co-processed system can create a commercial advantage when it reduces tablet weight, improves manufacturing yield, or allows a less expensive process. It does not create meaningful market exclusivity by itself.

What formulation patents protect the product?

The commercial protection for this product historically has been associated with the combination, dosage form, and related pharmaceutical compositions rather than with a novel excipient platform. Generic manufacturers must evaluate the current FDA Orange Book listings, any unexpired patents, regulatory exclusivity, and the reference product's labeling before filing an ANDA.[2]

The principal legal categories are:

Protection category	Relevance to this product
Active-ingredient patents	Potentially relevant to individual components, but the original compounds are mature
Combination patents	May cover the use or composition containing all three active ingredients
Formulation patents	May cover tablet composition, dosage ratios, or release characteristics
Method-of-use patents	May cover treatment of hypertension or patient subgroups
Manufacturing patents	May cover process-specific preparation or crystallization methods
Regulatory exclusivity	Relevant at launch and during any applicable exclusivity period

An ANDA applicant may use a Paragraph IV certification against an Orange Book-listed patent. A Paragraph III certification delays launch until patent expiration. A Section viii statement may be used when a listed method-of-use patent does not cover the proposed label.

Patent risk should be assessed separately for each jurisdiction. U.S. Orange Book status does not determine freedom to operate in Europe, Japan, Canada, or emerging markets.

When does generic competition affect commercial opportunity?

The original product's market has transitioned from branded exclusivity toward generic competition. The precise launch timing for any individual manufacturer depends on the current Orange Book, litigation outcomes, settlements, regulatory review, and commercial launch decisions.

The standard generic launch scenarios are:

1. At-risk launch before final patent resolution.
2. Launch after patent expiry.
3. Launch under a settlement date.
4. Launch after regulatory approval but without immediate commercial distribution.
5. Authorized-generic or contract-manufacturing supply.

For a mature triple combination, the highest-value generic opportunity usually belongs to manufacturers that can achieve approval and stable supply at low cost. A small tablet, low defect rate, and multi-strength manufacturing platform can improve gross margin even when list-price erosion is substantial.

What regulatory pathway applies to the combination?

A conventional generic version is generally submitted through an ANDA under Section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant must demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug.[3]

Key ANDA considerations include:

• Same active ingredients.
• Same dosage form and route of administration.
• Same strength.
• Same or equivalent labeling, subject to permissible differences.
• Bioequivalence.
• Acceptable impurities and degradation profile.
• Demonstrated batch reproducibility.
• Stability through the proposed shelf life.

A reformulated product with a new dosage form, clinically meaningful excipient change, or modified delivery system may require a 505(b)(2) application rather than an ANDA. The 505(b)(2) route can support product differentiation but carries higher development, clinical, regulatory, and intellectual-property costs.

Does the product have biosimilar risk?

No. Olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide are small-molecule active ingredients. The relevant competition is generic substitution, not biosimilar interchangeability.

What excipient substitutions create a commercial opportunity?

Excipient substitution can reduce cost and supply risk, but it must be managed as a product-performance change rather than a simple procurement decision.

Lactose-free or low-lactose formulations

Replacing lactose may target patients with lactose sensitivity or support a cleaner excipient profile. Candidate alternatives include mannitol, anhydrous dibasic calcium phosphate, pregelatinized starch, and additional microcrystalline cellulose.

The main technical issue is that each replacement changes density, flow, compaction, moisture behavior, and tablet size. A lactose-free version may require a new process window and may not qualify as a straightforward generic composition without supporting data.

Alternative binders and disintegrants

Hydroxypropyl cellulose can be replaced or supplemented with povidone, copovidone, or pregelatinized starch. Low-substituted hydroxypropyl cellulose can be replaced by croscarmellose sodium, sodium starch glycolate, or crospovidone.

These substitutions can accelerate disintegration, but faster disintegration does not automatically produce equivalent dissolution. The interaction with olmesartan medoxomil's wettability and particle size must be characterized.

Lubricant optimization

Magnesium stearate is widely used but can reduce wettability and slow dissolution when overused or blended for too long. Lower lubricant concentration, shorter lubrication time, or an alternative lubricant such as sodium stearyl fumarate may improve robustness.

This is a practical area for process optimization because a small change can affect tablet ejection force, dissolution, tensile strength, and stability.

Colorant and coating changes

Strength-specific color coding reduces dispensing errors. A manufacturer can use alternative iron oxide ratios or a different film-coating system, provided the tablets remain distinguishable and the labeling remains compliant.

Colorant changes create limited clinical differentiation but can reduce supply-chain dependence on a single pigment supplier.

What advanced dosage forms could create new commercial value?

The standard immediate-release tablet is difficult to differentiate on clinical grounds. Product developers may pursue a new dosage form when the commercial objective is to improve adherence, swallowing, or patient convenience.

Smaller tablets

A smaller tablet can improve swallowability and reduce packaging volume. It may be achieved through higher-density excipients, optimized granulation, or improved compression. The risk is reduced porosity and slower disintegration.

Orally disintegrating tablets

An orally disintegrating version could target patients with dysphagia or adherence difficulties. The formulation challenge is substantial because olmesartan medoxomil and the combined dose may require a relatively large drug load. Taste masking, mechanical strength, moisture protection, and rapid dispersion must be addressed.

Sprinkle or multiparticulate dosage forms

A sprinkle formulation could target patients who cannot swallow tablets. The active ingredients must remain chemically and physically stable when dispersed over soft food. Dose uniformity, taste, moisture sensitivity, and labeling complexity can limit the opportunity.

Modified-release or chronotherapeutic products

Modified release is technically possible but commercially less attractive unless it produces a clinically meaningful advantage. The three active ingredients have different pharmacokinetic and pharmacodynamic profiles, which complicates synchronized release.

A modified-release product would likely require a 505(b)(2) strategy and additional clinical or pharmacokinetic evidence. It would also face higher development costs and possible patent exposure.

How strong is the patent estate for the combination?

The patent estate is weaker as a long-term commercial barrier than the patent estate for a recently launched branded medicine because all three active ingredients are established small molecules and the product has been on the market since 2010.

The remaining risk is claim-specific. A narrow combination or formulation patent can still affect a generic applicant if the proposed product falls within the claims. The strongest claims would generally be those that cover:

• The specific three-drug combination.
• The approved dosage ratios.
• A defined pharmaceutical composition.
• A manufacturing process that is difficult to design around.
• A method of use required by the reference product label.

Broad claims directed to routine tablet excipients are less likely to create durable commercial exclusivity because generic developers can often substitute functionally equivalent excipients or use a different process.

What manufacturing and intellectual-property barriers matter most?

The most important barriers are operational rather than chemical.

Blend uniformity

Amlodipine is the lowest-dose active. Poor dispersion can cause assay and content-uniformity failures, particularly in direct-compression processes.

Dissolution control

Olmesartan medoxomil is the main formulation risk because its dissolution can be affected by particle size, wetting, compression, and lubricant exposure.

Multi-strength validation

Four strengths require a coherent control strategy. Bracketing and matrixing may reduce stability burdens, but the sponsor must demonstrate that the selected strengths represent the manufacturing range.

Impurity control

Each active ingredient has its own degradation and impurity profile. The combination product also requires evaluation of potential active-active and active-excipient interactions.

Packaging

Moisture protection can be important for tablet stability and coating integrity. High-barrier bottles, desiccants, or blister packaging may be used depending on stability data and regional requirements.

Supply resilience

A manufacturer dependent on a single supplier for lactose, microcrystalline cellulose, low-substituted hydroxypropyl cellulose, coating pigments, or a specialized active grade faces avoidable interruption risk. Dual sourcing can have greater commercial value than a novel excipient claim.

How does this product compare with related antihypertensive combinations?

Product type	Main advantage	Main limitation	Excipient opportunity
ARB plus calcium-channel blocker	Lower tablet burden than separate therapy	Does not include diuretic intensification	Smaller tablet and improved dissolution
ARB plus hydrochlorothiazide	Established two-drug platform	Less complete for resistant hypertension	Low-cost, high-volume generic production
Calcium-channel blocker plus hydrochlorothiazide	Simple combination	Does not include renin-angiotensin blockade	Standard immediate-release optimization
Triple ARB/calcium-channel blocker/diuretic	Maximum combination convenience	Larger dose load and more complex formulation	Adherence-oriented dosage forms and supply efficiency

The triple combination has a stronger adherence proposition than separate prescriptions but a narrower patient population than the individual components. Commercial success depends on whether prescribers and payers prefer a single tablet over lower-cost separate generics.

What licensing and partnership opportunities exist?

Licensing opportunities are more likely in manufacturing and regional commercialization than in fundamental formulation patents.

Potential deal structures include:

• Regional licensing of an approved generic.
• Contract manufacturing for pharmacy chains.
• Supply agreements with integrated healthcare systems.
• Technology transfer for direct compression or roller compaction.
• Co-development of lactose-free or low-size tablets.
• Authorized-generic distribution.
• API and excipient dual-sourcing partnerships.

The most attractive partner is often a manufacturer with an existing cardiovascular portfolio, validated tablet equipment, and distribution access. A standalone formulation license has limited value unless it provides measurable benefits in cost, stability, yield, or patient usability.

What revenue exposure exists for manufacturers?

Revenue exposure is determined by three factors:

1. Volume of patients receiving triple therapy.
2. Generic price erosion.
3. Ability to maintain supply across all four strengths.

The strongest commercial case is a portfolio approach covering:

• The triple combination.
• Olmesartan/amlodipine.
• Olmesartan/hydrochlorothiazide.
• Single-agent olmesartan.
• Amlodipine.
• Hydrochlorothiazide.

A manufacturer selling the complete progression from monotherapy to dual and triple therapy can improve formulary relevance and reduce customer-acquisition cost. The product is less attractive as a standalone SKU because demand is concentrated in a specific escalation segment.

Key Takeaways

• The product is a mature, small-molecule triple antihypertensive combination marketed originally as Tribenzor.
• The core excipient platform is conventional: lactose, cellulose-based fillers and disintegrants, hydroxypropyl cellulose, magnesium stearate, talc, and film-coating pigments.
• The main technical risks are amlodipine content uniformity, olmesartan medoxomil dissolution, and multi-strength process control.
• Generic development normally proceeds through an ANDA, while materially differentiated dosage forms may require a 505(b)(2) application.
• Biosimilar competition does not apply.
• The most credible commercial opportunities are low-cost generic manufacture, excipient dual sourcing, smaller tablets, lactose-free products, and adherence-oriented dosage forms.
• Patent risk should be assessed through current Orange Book listings and claim-by-claim freedom-to-operate analysis.
• Licensing value is strongest in regional distribution, contract manufacturing, and validated formulation technology.
• A broad cardiovascular product portfolio is commercially stronger than a standalone triple-combination launch.

FAQs

Can olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide be formulated as an orally disintegrating tablet?

Yes, but the combined active load, taste, tablet strength, moisture sensitivity, and dissolution behavior make an orally disintegrating tablet more difficult than the standard immediate-release tablet.

Is lactose removal likely to create a new patent position?

Usually not by itself. A lactose-free composition may support a formulation patent only if it includes a non-obvious excipient combination, manufacturing process, or performance advantage.

Which excipient has the greatest effect on dissolution?

Magnesium stearate level and lubrication time can materially affect wettability and dissolution. Disintegrant type, olmesartan particle size, and compression force are also important.

Would a generic manufacturer need clinical trials for an excipient-substituted tablet?

A conventional ANDA generally relies on pharmaceutical equivalence, bioequivalence, and quality data rather than new efficacy trials. A materially different dosage form or delivery system may require a 505(b)(2) pathway and additional clinical or pharmacokinetic evidence.

What is the strongest commercial differentiation for this product?

Reliable supply at competitive cost is the strongest near-term differentiator. Smaller tablets, lactose-free composition, improved packaging, and patient-friendly dosage forms offer secondary opportunities.

References

1. Daiichi Sankyo, Inc. (2010). Tribenzor: Prescribing information. U.S. Food and Drug Administration labeling archive.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th edition. FDA.

3. U.S. Food and Drug Administration. (2023). Abbreviated new drug application submissions: Content and format of an ANDA. FDA.

4. U.S. Food and Drug Administration. (2024). Inactive ingredient database. FDA.

5. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.

6. U.S. Food and Drug Administration. (2015). Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. FDA.